# Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

Source: https://onco.cc/trials/nct07211958/  
OnCo record `nct07211958` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Revumenib in acute myeloid leukaemia, run by Syndax Pharmaceuticals, now recruiting.

## Summary

Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation is a phase 3 interventional study registered as NCT07211958 by Syndax Pharmaceuticals, with 468 participants planned, started 2025-11-25 and due to reach its primary completion in 2029-06. Interventions recorded: Revumenib, Placebo and Intensive Chemotherapy Regimen.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07211958
- Phase: 3
- Setting: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Newly Diagnosed AML With an NPM1 Mutation
- Sponsor: Syndax Pharmaceuticals
- Enrolled: 468

## Sources

- ClinicalTrials.gov NCT07211958: https://clinicaltrials.gov/study/NCT07211958

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- drugs: [Revumenib](https://onco.cc/drugs/revumenib/)
- companies: [Syndax Pharmaceuticals](https://onco.cc/companies/syndax/)

---
JSON: https://onco.cc/api/v1/entities/nct07211958.json